«…Whether or not MannKind Corporation topped estimates last quarter is largely a matter of perspective. The loss of eight cents per share of MNKD was in line with some estimates, andactually topped others. Though the company didn’t offer an official revenue number for its first quarter, it did confirm it booked $7.1 million worth of AFREZZA shipments as deferred product sales, which could arguably substitute for sales, which would have topped estimates.

It’s not the Q1 numbers, however, that sent MNKD shares more than 5% lower on Friday. **** It was the lack of visibility and guidance ****. While most of the market understands it’s a new enterprise and any guidance is only offered on a best-guess basis, the company’s management seems oddly unconcerned about the slow launch and growing debt.

Investors may be increasingly concerned that not everything is as hunky-dory as was once believed …»

Como bien dice Framus la mosca es muy cojonera y cuando la pilla con alguna no para hasta que los datos le hagan callar.

Yo creo que va mas en plan de coñita-marinera que otra cosa.
El «innombrable» no cambia de parecer así como así.

Esto es lo que escribió hace unos dias:
http://www.thestreet.com/story/13045219/1/biotech-stock-mailbag-mannkind-mast-therapeutics-bluebird.html

Framus

Suerte a los que estáis dentro…aunque la mosca cojonera es mucha mosca.